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ABSTRACT 23 
 24 
In this paper, a survey of our studies on almond polyphenols including their chemical 25 
characterization and further bioavailability in humans is reported. Combination of analytical 26 
techniques (LC-DAD/fluorescence, LC/ESI-MS and MALDI-TOF) allowed us, for the first 27 
time, the identification of A- and B-type procyanidin, propelargonidin and prodelphinidin 28 
polymers in almond skins. Glucuronide, O-methyl glucuronide, sulfate and O-methyl sulfate 29 
derivatives of (epi)catechin, as well as the glucuronide conjugates of naringenin and 30 
isorhamnetin,  and sulfate conjugates of isorhamnetin, together with conjugates of 31 
hydroxyphenylvalerolactones were detected in plasma and urine samples after the intake of 32 
almond skin polyphenols. In addition, numerous microbial derived metabolites, including 33 
hydroxyphenylpropionic, hydroxyphenylacetic, hydroxycinnamic, hydroxybenzoic and 34 
hydroxyhippuric acids were also identified. Depending of the type of metabolite, maximum 35 
urinary excretion was attained at different time in comparison to the control group in the 36 
course of the 24-h period of urine excretion, allowing us to establish the onset of microbial 37 
metabolism.  38 
 39 
 40 
 41 
 42 
 43 
 44 
 45 
 46 
Key words. Almond skins; flavan-3-ols; conjugated phenolic metabolites; microbial-derived 47 
phenolic metabolites; hydroxyphenylvalerolactones; targeted analysis 48 
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1. INTRODUCTION 49 
Among others foods, nuts have been traditionally associated with the Mediterranean diet. 50 
Regular nut consumption, in moderate doses, has been proved to reduce the blood levels of 51 
total and LDL cholesterol, parameters which are associated with a lower incidence of 52 
cardiovascular and obesity related diseases [1]. These healthy effects are attributed, in 53 
addition to their lipid profile and other components, to the presence of antioxidant phenolic 54 
compounds [2]. In particular, the consumption of whole almonds decreases postprandial 55 
glycemia, insulinemia and oxidative protein damage in healthy subjects [3]. Also, almond 56 
skin polyphenols have been found to act in synergy with vitamins C and E to protect LDL 57 
from oxidation and to enhance antioxidant defense [4,5]. A reduction in the risk of cancer and 58 
cardiovascular disease has also been described [6]. 59 
 60 
Almonds (Prunus dulcis (Mill.) D.A. Webb) are eaten raw, roasted and fried; but can also be 61 
used as ingredients in different products such as sauces, snacks and traditional Spanish 62 
products such as marzipan and “turron”. Also, almonds are processed to make nutritional 63 
products such as almond milk used as a substitute cow’s milk [7]. Industrial processing of 64 
almonds implies the sequential removal of the external coatings (mesocarp and brown hull) to 65 
obtain the whole almond with its skin. In further steps, whole almonds can be subjected to 66 
roasting and part of the skin falls apart, or alternatively they can be blanched to get peeled 67 
almonds [8]. The skin represents ?4% of the total almond weight and contains 70–100% of 68 
total phenols present in the nut [9].   69 
 70 
The phenolic composition of almond skin comprises both low molecular-mass compounds 71 
and high molecular-mass polymers. Different phenolic structures corresponding to 72 
hydroxybenzoic acids and aldehydes, hydroxycinnamic acids, flavan-3-ols, flavonol 73 
glycosides and aglycones, flavanone glycosides and aglycones, and dihydroflavonol 74 
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aglycones, have been identified in almond skins [10]. In relation to the high molecular-mass 75 
phenolics, A- and B-type procyanidins and propelargonidins up to heptamers, and A- and B-76 
type prodelphinidins up to hexamers also have been detected [8,10].  77 
 78 
Any hypothesis about the contribution of almond skin polyphenols to the health benefits 79 
associated with almond consumption has necessary to prove that these almond polyphenols 80 
are bioavailable in human. The first bioavailability studies of almond skins polyphenols were 81 
performed in rats [4] and humans [11], flavonoid aglycones being only quantified in pre-82 
hydrolysed plasma samples. Also, the bioaccessibility of phytochemicals from almond skins 83 
during gastrointestinal digestion and the role played by cell walls have been described using a 84 
dynamic gastric model of digestion [12, 13]. 85 
 86 
In this paper, we have summarized our recent studies covering from the previous 87 
characterization of almond skin polyphenols to their bioavailability in humans. A screening of 88 
both low and high molecular-mass of almond skins was first carried out using LC-89 
DAD/fluorescence, LC/ESI-MS and MALDI-TOF.  In order to determine the influence of the 90 
industrial processing on the phenolic composition of almond skins, samples submitted to 91 
different processes including  blanching, blanching+drying and roasting were compared. Our 92 
next goal was to assess the phenolic metabolite profile in plasma and urine after an intake of 93 
almond polyphenols in humans through a pilot study. After that, a comparative placebo-94 
controlled study was carried out in order to perform a targeted analysis of phenolic 95 
metabolites in urine samples, and finally to determine changes in the urinary metabolome 96 
after the intake of almond polyphenols. 97 
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2. MATERIALS AND METHODS 98 
 99 
2.1. Standards and reagents. Phenolic standards were obtained from Extrasynthèse (Genay, 100 
France), Sigma/Aldrich (St. Louis, MO, USA),  Fluka (Buchs, Switzerland) and PhytoLab 101 
GmbH&Co.KG (Vestenbergsgreuth, Germany).  β-Glucuronidase/sulfatase (from Helix 102 
pomatia;  85,000 units/mL of glucuronidase) was purchased from Sigma-Aldrich (St. Louis, 103 
MO). The solvents used (methanol, acetonitrile, acetic acid and formic acid) were of LC 104 
grade.  105 
 106 
2.2. Almond skin samples. Almond skins from mixtures of Spanish (harvest 2004) and 107 
American varieties of almonds (harvest 2004 and 2006) were kindly supplied by La Morella 108 
Nuts (Tarragona, Spain). Whole almonds were subjected to two different industrial processes: 109 
(a) blanching (95 ºC, 3 min) followed by peeling to remove the skins, and (b) roasting (145 110 
ºC) in a continuous-working oven where the skins (roasted samples) were separated from the 111 
roasted kernels. The wet skins obtained from the blanching process were then freeze-dried in 112 
the laboratory [blanched (freeze-dried) samples] or dried in an industrial hot-air oven at 60 ºC 113 
(blanched+dried samples) until constant moisture content of skins was reached.  114 
 115 
For the determination of total phenolic content, blanched, blanched+dried and roasted skins 116 
were milled in a Janke & Kunkel mill (Ika Labortechnik, Wilmington, North Carolina, USA). 117 
Ground skins (0.05 g) were extracted with 10 mL of methanol/HCl (1000:1, v/v) by 118 
sonication for 5 min followed by an extra 15 min resting period.  The mixture was then 119 
centrifuged (3024 g, 5 min, 5 ºC) and filtered (0.45 µm) for the determination of total 120 
phenolic content by the method of Singleton and Rossie [14]. Gallic acid was used as standard 121 
to prepare the calibration curve. The results were expressed as mg of gallic acid equivalents 122 
per gram of almond skin. Analysis was performed in triplicate. 123 
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 124 
 125 
For the human studies, a commercial almond skin extract (Amanda) made from the Spanish 126 
Marcona variety, was kindly supplied by Puleva Biotech, S.A (Granada, Spain). The almond 127 
skin extract consisted of water extraction at 60 °C followed by purification by adsorption 128 
chromatography using water-alcohol mixtures. The extract was encapsulated (350 mg extract 129 
+ 50 mg cellulose per capsule) by the supplier. The phenolic composition of the encapsulated 130 
almond skin extract was determined by LC-DAD-fluorescence and LC-DAD-ESI-MS [15, 131 
16]. Total non-flavonoid phenolic compounds (protocatechuic acid, ellagic acid and vanillic 132 
acid) accounted for 517 ± 63 µg/g of the encapsulated extract. The total concentration of the 133 
different groups of flavonoid phenolic compounds was:  2047 ± 215 µg/g for flavonols 134 
(aglycones and -3-O-galactosides, -3-O-rutinosides and -3-O-glucosides of kaempferol and 135 
isorhamnetin); 123 ± 17 µg/g for  flavanones (aglycones and -7-O-glucosides of naringenin 136 
and eriodictyol); 47.0 ± 8.1 µg/g for dihydroflavonols (dihydroquercetin); 975 ± 90 µg/g for 137 
monomeric flavan-3-ols [(+)-catechin and (-)-epicatechin], and 1282 ± 101 µg/g for 138 
olygomeric flavan-3-ols (A- and B-type properlagonidins and procyanidins). The  139 
encapsulated almond skin extract presented a total polyphenol content of 221 ± 6 mg gallic 140 
acid/g, a total proanthocyanidin content of 315 ± 14 mg cyanidin/g, and an antioxidant 141 
capacity (ORAC value) of 3.10 ± 0.20 mg mmol Trolox equivalents/g [15]. 142 
 143 
2.3. Determination of the phenolic composition of almond skins by LC-DAD-144 
fluorescence and MALDI-TOF MS 145 
For phenolic extraction, 2.10 g of ground skins were mixed with 30 mL of methanol/HCl 146 
(1000/1, v/v) and sonicated for 15 min followed by an extra 15 min of resting period. This 147 
procedure was performed twice. The mixture was then centrifuged (3024 g, 10 min, 5 ºC). 148 
The supernatant was separated and the pellet was submitted to two further extractions. The 149 
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supernatants were combined and the mixture was dried under vacuum. The residue was 150 
dissolved in 40 mL of distilled water and extracted with ethyl acetate (40 mL x 4). The 151 
organic phases were combined and dried with anhydrous Na2SO4 for 20 min. The extract was 152 
then taken to dryness under vacuum, dissolved in 2 mL of methanol/H2O (50:50, v/v), and 153 
finally filtered (0.45 µm) for HPLC analysis. The extractions were performed in duplicate. 154 
 155 
For the LC analysis, a Waters (Milford, MA, USA) liquid chromatography system equipped 156 
with a 600-MS controller, a 717Plus autosampler, a 996 photodiode-array detector (DAD), 157 
and a fluorescence detector coupled to the Waters Empower (version 5.0) for data acquisition 158 
and processing was used. Separation was performed on a 250 x 4.6 mm r.d., 4µm reversed-159 
phase Nova-Pak C18 (Waters, Milford, MA, USA) column at room temperature. A gradient 160 
consisting of solvent A (water/acetic acid, 98/2, v/v) and solvent B (water/acetonitrile/acetic 161 
acid, 73/25/2, v/v/v) was applied at a flow rate of 1.0 mL/min as follows [10]: 0-80 % B 162 
linear from 0 to 55 min, 80-90% B linear, from 55 to 57 min, 90% B isocratic from 57 to 70 163 
min, 90-95% B linear from 70 to 80 min, 95-100% B from 80 to 90 min, followed by washing 164 
(methanol) and re-equilibration of the column from 90-120 min. A 75 µL volume sample was 165 
injected into the column. The detection conditions were: 210-360 nm (DAD); 280 nm and 310 166 
nm for the emission and excitation filters, respectively (fluorescence detector). Quantification 167 
was carried out by external standard calibration curves. All of the phenolic compounds were 168 
quantified at 280 nm, except flavan-3-ols that were quantified by their fluorescence response. 169 
Due to the lack of commercial standards, oligomeric flavan-3-ols were quantified using the (-170 
)-epicatechin calibration curve.  171 
 172 
For the MALDI-TOF analysis, the ethyl-acetate-purified extracts (1µL) were mixed with 4 µL 173 
of the matrix consisting of 2,5-dihydroxybenzoic acid (gentisic acid) at a concentration of 20 174 
mg/mL in water [10]. Then, 1µL of this solution was spotted onto a flat stainless-steel sample 175 
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plate and dried in air. MALDI-TOF measurements were performed using a Voyager DE-PRO 176 
mass spectrometer (Applied Biosystems, Foster City, CA, USA) equipped with a pulsed 177 
nitrogen laser (=337 nm, 10 ns pulse width, and 20 Hz frequency) and a delayed extraction 178 
ion source. Ions generated by the laser desorption were introduced into the flight tube (1.3 m 179 
flight path) with an acceleration voltage of 25 kV, 94% grid voltage, 0.05% ion guide wire 180 
voltage, and a delay time of 100 ns in the linear positive ion mode. All mass spectra were 181 
collected by averaging the signals of at least 3000 laser shots over the m/z range 300-6000. 182 
Angiotensin I and bovine insulin were used for external calibration. 183 
 184 
2.4. Pilot study of acute intake of almond polyphenols in humans. Two healthy and non-185 
medication-receiving volunteers were recruited. They were advised to avoid alcohol and 186 
vegetable- and fruit-containing foods and beverages for 48 h before the study. In the morning 187 
(9.00), after overnight fasting, the volunteers ingested 10 capsules containing the almond skin 188 
extract (884 mg total polyphenols/dose), which was ∼8 times higher than the estimated dietary 189 
intake (102 to 121 mg/person/day) of nut polyphenols in the Spanish diet [17]. The volunteers 190 
did not consume any food before or with the almond skin extract. At 14.00, volunteers had a 191 
light lunch meal composed of pasta and meat, and at 20.00 they had a dinner meal composed 192 
of ham and bread. Venous blood samples were collected into vacuum tubes containing EDTA 193 
before and after ingestion (2.5 h for both volunteers and 4.5 h for volunteer #2). After 194 
sampling, blood was placed on ice, and plasma was separated by centrifugation for 20 min at 195 
1500 g at 4 ºC and stored at -80 ºC. Urine samples were also collected at the following 196 
intervals: from 2 h before the time of ingestion (-2–0 h, before extract intake), and from the 197 
time of ingestion to 24 h after ingestion (0–24 h, after extract intake). Urine samples were 198 
acidified to 0.2 M HCl, and were stored at -80 ºC. The study protocols were approved by the 199 
Ethics Committee of Clinical Investigation of the University of Barcelona (Spain) and 200 
informed consent was obtained from all participants. 201 
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 202 
 2.5. Placebo-controlled study of acute intake of almond polyphenols in humans. Six-teen 203 
healthy and non-receiving medication volunteers [n = 12 for the intake group, and n= 4 for 204 
the placebo (control) group] aged 29.8 ± 5.2 years were recruited for the study. Volunteers 205 
followed the same diet protocol before and during the day of the intake as in the pilot study. 206 
The intake group ingested the same dosis of almond skin polyphenol extract (10 capsules) 207 
whereas the control group ingested 10 capsules containing 450 mg of microcrystalline 208 
cellulose. But for this study, urine samples were collected in the following time periods: from 209 
2 h before to the time of intake [(-2)-0 h]; from time of intake (0 h) to 2 h after intake (0-2 h); 210 
from 2 h to 6 h after intake (2-6 h); from 6 h to 10 h after intake (6-10 h), and from 10 h to 24 211 
h after intake (10-24 h). Urine samples were acidified to 0.2 M HCl, and were stored at -80 212 
ºC. The study protocols were approved by the Ethics Committee of Clinical Investigation of 213 
the University of Barcelona (Spain) and informed consent was obtained from all participants. 214 
 215 
2.6. Enzymatic hydrolysis of plasma and urine samples.  216 
Samples were subjected to enzymatic hydrolysis as previously described Urpi-Sarda et al. 217 
[18]. Briefly, urine samples (1 mL) were taken to pH 4.9 with 200 µL of 2 M sodium acetate, 218 
and subsequently incubated with -glucuronidase/sulfatase (9444 units/mL of glucuronidase) 219 
at 37ºC for 45 min. Straight afterwards, samples were acidified to pH 2 with 6 M HCl.  220 
 221 
2.7. Extraction of phenolic metabolites from plasma and  urine samples.  222 
To perform the targeted analysis of microbial-derived metabolites, extraction from 223 
hydrolyzed samples was performed using solid-phase extraction (SPE) Oasis® MCX 96-well 224 
plates (Waters, Mildford, Massachusetts), a vacuum manifold and a vacuum source as 225 
described by Urpi-Sarda et al [18]. Briefly, the plate was conditioned with 1mL of methanol 226 
followed by 1 mL of 2% formic acid. The hydrolyzed urine samples were then loaded onto 227 
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the plate with 100 µL of 2 µM ethyl gallate as internal standard (IS). The plate was washed 228 
with 1 mL of 2% formic acid. Analytes were then eluted with methanol (0.5 mL x 3) and the 229 
eluates were evaporated to dryness under a stream of nitrogen. Residues were reconstituted 230 
with 100 µL of mobile phase.  231 
 232 
For the targeted analysis of conjugated metabolites, non-hydrolyzed samples were 233 
fractionated by SPE, using Oasis HBL 96-well plates (30 mg) (Waters, Mildford, 234 
Massachusetts). The plate was conditioned with 1mL of methanol followed by 1 mL of 1.5 M 235 
formic acid. One milliliter of the non-hydrolyzed urine samples were then loaded onto the 236 
plate with 100 µL of 2 µM ethyl gallate used as internal standard (IS). The plate was washed 237 
with 1 mL of 1.5 M formic acid and 1 mL of 5% methanol.  The plates were thoroughly dried 238 
by vacuum. Analytes were then eluted with 2 ml of methanol containing 0.1% formic acid 239 
and 2 ml of methanol containing NH3 (pH=5) and the eluates were evaporated to dryness 240 
under a stream of nitrogen. Residues were reconstituted with 100 µL of mobile phase.  241 
 242 
2.8. Analysis of phenolic metabolites in urine and plasma samples by LC-ESI-MS/MS.  243 
The analysis of phenolic metabolites in urine and plasma samples were carried out by LC-244 
ESI-MS/MS on a Agilent 1200 system equipped with a quaternary pump and a refrigerated 245 
autosampler plate (Waldbronn, Germany), and coupled to an Applied Biosystems API 3000 246 
Triple Quadrupole mass spectrometer (PE Sciex, Concord, Ontario, Canada) equipped with a 247 
Turbo IonSpray ionizing in negative mode. A Phenomenex Luna C18 analytical column [50 x 248 
2.0 mm i.d., 5µm] (Torrance, CA) with mobile phase A (100% water and 0.1% formic acid) 249 
and B (100% acetonitrile and 0.1% formic acid) was used as described by Urpi-Sarda et al 250 
[15]. For the non-hydrolyzed samples, the gradient was linear of 4-100% of mobile phase B 251 
from 0 to 8 min followed by washing and re-equilibration of the column for 2 min, at a flow 252 
rate of 500 L/min. For the hydrolyzed samples, the gradient was linear of 8-100% of mobile 253 
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phase B from 0 to 7 min followed by washing and re-equilibration of the column for 3 min at 254 
a flow rate of 400 L/min. The volume injected was 15 L. MS/MS parameters used were as 255 
follows: capillary voltage, -3700 V; focusing potential, -200 V; entrance potential, -10 V; 256 
declustering potential, -50 V; nebulizer gas, 10 (arbitrary units); curtain gas, 12 (arbitrary 257 
units); collision gas, 5 (arbitrary units); auxiliary gas temperature, 400ºC; auxiliary gas flow 258 
rate, 6000 cm3/min. For quantification purposes data were collected in the multiple reaction 259 
monitoring (MRM) mode, tracking the transition of parent and product ions specific for each 260 
compound with a dwell time of 100 ms. For the conjugated metabolites of flavan-3-ols, the 261 
following transitions were targeted: (epi)catechin-O-glucuronide (465/289), O-methyl 262 
(epi)catechin-O-glucuronide (479/303), (epi)catechin sulfate (369/289), and O-methyl 263 
(epi)catechin sulfate (383/303). For conjugated metabolites of hydroxyphenylvalerolactones, 264 
the following transitions were targeted: 5-(dihydroxyphenyl)--valerolactone glucuronide 265 
(383/207); 5-(dihydroxyphenyl)--valerolactone sulfate (287/207); 5-(hydroxy-methoxy-266 
phenyl)--valerolactone glucuronide (397/221); 5-(hydroxy-methoxy-phenyl)--valerolactone 267 
sulfate (301/221). For the conjugated metabolites of flavonols, the following transitions were 268 
targeted: naringenin-O-glucuronide (447/271); isorhamnetin-O-glucuronide (491/315), and 269 
isorhamnetin sulfate (395/315). For microbial-derived phenolic metabolites, the following 270 
transitions were targeted: 5-(dihydroxyphenyl)--valerolactone (207/163); 5-(hydroxyphenyl)-271 
-valerolactone (191/147); 3,4-dihydroxyphenylpropionic acid (181/137); 3-272 
hydroxyphenylpropionic acid (165/121); 3,4-dihydroxyphenylacetic acid (167/123); 3-273 
hydroxyphenylacetic acid (151/107); 4-hydroxy-3-methoxy-phenylacetic acid (181/137); 274 
phenylacetic acid (135/91); m-coumaric acid (163/119); p-coumaric acid (163/119); caffeic 275 
acid (179/135); ferulic acid (193/134); 3-hydroxy-4-methoxy-cinnamic acid (193/134); 3-276 
hydroxybenzoic acid (137/93); 4-hydroxybenzoic acid (137/93); protocatechuic acid 277 
(153/109); vanillic acid (167/152), and 4-hydroxyhippuric acid (194/100). 278 
 279 
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Phenolic standard curves were constructed with standard solutions subjected to the same SPE 280 
procedure than the samples. Conjugated metabolites of (epi)catechin, naringenin and 281 
isorhamnetin were quantified using the calibration curves of (-)-epicatechin, naringenin and 282 
isorhamnetin, respectively. Hydroxyphenylvalerolactones and their conjugated metabolites 283 
were quantified as (-)-epicatechin. 284 
 285 
2.9. Statistical methods. The statistical methods used for data analysis were: a) Repeated 286 
Measures Analysis of Variance (ANOVA) to test jointly the effects of the two factors: time as 287 
within-subjects factor, with 5 levels: (-2)-0 h,  (0-2 h), (2-6 h), (6-10 h) and (10-24 h), and the 288 
groups of consumption of almond skin extracts (intake and control), as a categorical factor; b) 289 
and Principal Component Analysis (PCA), from standardized variables, to examine the 290 
relationship between all targeted metabolites at all time periods. The STATISTICA program 291 
for Windows, version 7.1 was used for data processing (StatSoft, Inc., 2005, 292 
www.statsoft.com).  293 
 294 
3. RESULTS 295 
3.1. Characterization of phenolic compounds from almond skins  296 
A total of 31 low molecular-mass phenolic compounds were identified and quantified (Table 297 
1) in almond skins by LC-DAD/fluorescence and  LC/ESI-MS using their retention time and 298 
UV and mass spectra [10]. These compounds corresponded to different flavonoids and non-299 
flavonoids: hydroxybenzoic acids (p-hydroxybenzoic acid, vanillic acid, and protocatechuic 300 
acid) and aldehydes (protocatechuic aldehyde), hydroxycinnamic acids (trans-p-coumaric 301 
acid and 3-O-caffeoylquinic acid), flavan-3-ols ((+)-catechin, (–)-epicatechin, procyanidins 302 
B3, B1, B2, B7, B5, C1, three unknown A-type procyanidin dimers and an unknown A-type 303 
procyanidin trimer), flavonol glycosides (kaempferol-3-O-rutinoside, kaempferol-3-O-304 
glucoside, isorhamnetin-3-O-rutinoside, isorhamnetin-3-O-glucoside, and quercetin-3-O-305 
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glucoside), flavanone glycosides (naringenin-7-O-glucoside and eriodictyol-7-O-glucoside), 306 
flavonol aglycones (kaempferol, quercetin, and isorhamnetin), dihydroflavonol aglycones 307 
(dihydroquercetin) and flavanone aglycones (naringenin and eriodictyol).  308 
 309 
Concerning high-molecular mass flavan-3-ol polymers, Table 2 describes the [M+Na]+ 310 
signals detected by MALDI-TOF-MS in the almond skin extracts [10]. They corresponded to 311 
a series of A-type (containing one A-type linkage) and B-type (oligomers and polymers 312 
composed of: i) homopolymers of (epi)catechin (procyanidins), ii) heteropolymers composed 313 
of one (epi)afzelechin unit and the rest of (epi)catechin units (propelargonidins), and iii) 314 
heteropolymers containing one unit of (epi)gallocatechin unit and the rest of (epi)catechin 315 
units (prodelphinidins) (Table 2). A- and B-type procyanidins and propelargonidins were 316 
detected up to heptamers, and A- and B-type prodelphinidins up to hexamers (Table 2). 317 
 318 
3.2. Influence of industrial processing 319 
The total polyphenol content of skins from mixtures of Spanish and American almond 320 
varieties ranged from 9.10 to 32.1 mg of gallic acid equivalents per gram of almond skin. 321 
Both roasted skins and blanched+dried skins showed a higher phenolic content than blanched 322 
skins (1.9-2.8-fold and 1.2-1.6-fold increase, respectively) [8]. 323 
Figure 1 illustrates the influence of industrial processing on the content of individual phenolic 324 
by group category: Σ hydroxybenzoic acid and aldehydes, Σ hydroxycinnamic acids, Σ flavan-325 
3-ols, Σ flavonol glycosides, Σ flavanone glycosides, Σ flavonol aglycones, Σ dihydroflavonol 326 
aglycones, and Σ flavanone aglycones. Comparing roasted skins (R) with blanched skins (B) , 327 
the phenolic content of the different phenolic groups was approximately 2-fold higher in R 328 
samples, except for Σ flavonol aglycones. Differences in phenolic content were more relevant 329 
for Σ flavan-3-ols and Σ flavonol glycosides which are the main phenolic groups in almond 330 
skins (Figure 1). 331 
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Similarly, industrial drying of blanched almond skins (BD) produced an increase in the 332 
content of the different phenolic groups (Figure 1). Again, these differences were more 333 
relevant for Σflavan-3-ols and Σflavonol glycosides. An increase in the content of Σ 334 
hydroxybenzoic acids and aldehydes, Σ hydroxycinnamic acids and Σflavanone glycosides, 335 
was also observed but not for all varieties. However, Σ flavonols and Σ flavanone aglycones 336 
showed a decrease of phenolic content in BD samples (Figure 1). 337 
 338 
3.3. Identification of phenolic metabolites in human plasma and urine 339 
To determine the main phenolic metabolites originated from the ingestion of almond 340 
polyphenols, a pilot study with two healthy volunteers was first carried out. Plasma (0 h and 341 
2.5 h after the intake) and urine samples (2-0 h before the intake and 0-24 h after the intake) 342 
were subjected to hydrolysis for the determination of microbial-derived phenolic acids. Non-343 
hydrolyzed samples were used for the determination of the phenolic conjugated forms. 344 
 345 
A total of 22 conjugates derived from phase II metabolism of flavanols, flavonols, flavanones, 346 
and hydroxyphenylvalerolactones (a microbial metabolite of flavan-3-ols) [19-21] were 347 
identified in non-hydrolyzed samples (Table 3). For all these metabolites, an increase in 348 
concentration was observed after the intake of the almond skin extract (Table 3). The majority 349 
of the metabolites were detected in both plasma and urine samples, except for the conjugates 350 
of hydroxyphenylvalerolactones and isorhamnetin that were mainly detected in urine (0-24 h). 351 
This could be attributed to the fact that their formation from the microbial degradation from 352 
flavan-3-ols and isorhamnetin-3-O-rutinoside, respectively, may require a longer period of 353 
time [15]. 354 
 355 
The following microbial-derived phenolic acids were detected in the hydrolyzed samples: 3,4-356 
dihydroxyphenylpropionic, 3-hydroxyphenylpropionic, 3,4-dihydroxyphenylacetic, 3-357 
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hydroxyphenylacetic,  4-hydroxy-3-methoxy-phenylacetic,  phenylacetic, m- and  p-coumaric, 358 
caffeic, ferulic, 3-hydroxy-4-methoxy-cinnamic,, 3-hydroxybenzoic, 4-hydroxybenzoic, 359 
protocatechuic, vanillic, and 4-hydroxyhippuric (Table 3). All targeted metabolites were 360 
identified in plasma and urine samples with the exception of 3-hydroxybenzoic acid in 361 
plasma. In the case of urine samples, an increase in the concentration of all metabolites was 362 
observed 24 h after the intake of the almond skin extract. However, no changes were observed 363 
in plasma after 2.5 h from the intake, which was expected since this was a short time for the 364 
formation of these metabolites by the microbiota. 365 
 366 
3.4. Targeted analysis of the phenolic metabolites in urine samples 367 
A further placebo-controlled study was carried out with sixteen healthy and non-receiving 368 
medication volunteers (n = 12 for the intake group, and n = 4 for the control group) targeting 369 
the metabolites above identified in urine after the intake of the almond skin extract. As 370 
representative results, Figure 2 illustrates the changes registered in the urinary levels of 371 
(epi)catechin sulfate #1, 5-(hydroxymethoxyphenyl)--valerolactone sulfate #1, naringenin-O-372 
glucuronide #1, isorhamnetin sulfate, 3,4-dihydroxyphenylpropionic acid, 4-hydroxy-3-373 
methoxy-phenylacetic acid, caffeic acid, and protocatechuic acid. 374 
 375 
For (epi)catechin sulfate #1 and naringenin-O-glucuronide #1 significant changes (p < 0.05) 376 
were observed for the time period of urine collection, and between the intake and control 377 
groups (Figure 2A and 2C). The urinary excretion of these metabolites increased from (-2)-0 378 
h to 0-2 h after the intake, reaching the maximum level at 2-6 h. For isorhamnetin sulfate, 379 
significant changes (p < 0.05) were only registered for the time period of urine collection, 380 
although the urinary excretion of last fraction (10-24 h) was higher for the intake group 381 
(Figure 2D). 382 
 383 
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Concerning the conjugated forms of hydroxyphenylvalerolactones, significant changes (p < 384 
0.05) were registered for 5-(hydroxymethoxyphenyl)--valerolactone sulfate #1 for the time 385 
period, and between the intake and control groups (Figure 2B). The excretion of this 386 
compound started at 2-6 h after the intake, and kept increasing up to 10-24 h after the intake. 387 
 388 
Concerning microbial-derived metabolites, changes in the levels of 3,4-389 
dihydroxyphenylpropionic acid (Figure 2E), 4-hydroxy-3-methoxy-phenylacetic acid (Figure 390 
2F), caffeic acid (Figure 2G), and protocatechuic acid (Figure 2H) were only significant (p < 391 
0.05) for the time period of sample collection. Therefore, the small differences observed in the 392 
urinary excretion levels between intake and control groups in the course of the 24-h period, 393 
suggested the need of a larger time period for these microbial-derived metabolites to be 394 
excreted. 395 
 396 
To determine the influence of both conjugated and microbial-derived phenolic metabolites in 397 
the urinary metabolome as consequence of the intake of the almond skin extract, a PCA was 398 
performed including all targeted metabolites at all time periods. Two new components, PC1 399 
(that explained 37.7% of the total variance of the data) and PC2 (that explained 20.2% of the 400 
total variance of the data) resulted from the analysis (Figure 3). PC1 was negatively correlated 401 
with 5-(dihydroxyphenyl)--valerolactone sulfate, 5-(hydroxy-methoxy-phenyl)--402 
valerolactone glucuronide #1, 5-(hydroxy-methoxy-phenyl)--valerolactone sulfate #1, 4-403 
hydroxyhippuric acid, 3- and 4-hydroxybenzoic acids, protocatechuic acid, phenylacetic acid, 404 
3,4-dihydroxyphenyl acetic acid, 4-hydroxy-3-methoxy-phenylacetic acid, m-coumaric acid, 405 
caffeic acid, ferulic acid, and 3-hydroxy-4-methoxy-cinnamic acid (loadings < -0.7). This is to 406 
mean, PC1 was more related to metabolites of microbial origin. Contrary, PC2 was positively 407 
correlated with (epi)catechin-O-glucuronide #3, O-methyl (epi)catechin-O-glucuronide #1 408 
and #2, (epi)catechin sulfate #1 and #2, and O-methyl (epi)catechin sulfate #1, #2 and #3 409 
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(loadings > 0.7), so PC2 was more related to conjugated metabolites formed after the intake 410 
of the almond polyphenols. In addition, it is important to highlight that urine samples were 411 
distributed in the plane defined by these two components according to the time period of 412 
sample collection: (-2)-0 h, 0-2 h, 2-6 h, 6-10 h, and 10-24 h (Figure 3). 413 
 414 
4. DISCUSSION 415 
 416 
Our results concerning the phenolic composition of almond skins from different origins and 417 
harvests, suggested that almond skin can be considered as a good source of polyphenols to be 418 
used in the elaboration of dietary ingredients. The total polyphenol content of almond skin is 419 
≥ 10 mg per gram, which is higher than other well-known materials such as red grape skin, 420 
but lower than grape seeds [8]. From the data of the individual phenolic compound content, it 421 
can be stated that the phenolic composition of almond skins is characterized by the prevalence 422 
of flavan-3-ols (represented 33-56% of the total compounds identified for the different 423 
almond varieties) and  flavonol glycosides (9-36%). Other minor phenolic compound found in 424 
almond skins corresponded to hydroxybenzoic acids and aldehydes (6-26%), flavanol 425 
aglycones (1.7-18%), flavanol glycosides (3-7.7%), flavanone aglycones (0.69-5.4%), 426 
hydroxycinnamic acids (0.65-2.6%), and dihydroflavonol aglycones (0-2.8%) [8]. Also, the 427 
most abundant compounds present in almond skin was (+)-catechin, representing 10-23 % of 428 
the total phenolic compounds identified, and isorhamnetin-3-O-rutinoside accounting for 6.8-429 
17% [8]. 430 
 431 
Although almonds can eaten raw, almonds are usually subjected to industrial processing to 432 
remove the skin. Our results indicate that the phenolic content of almond skins depends on the 433 
industrial processing used. Subjecting the almonds to high temperatures (i.e., blanching, 434 
drying, roasting) could promote degradation of polymeric compounds such as 435 
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proanthocyanidins [22], hydrolysis of glycosylated flavonoids [23] and the decomposition of 436 
the aglycones [24], which could explain the increase observed in the content of monomeric 437 
and oligomeric flavan-3-ols after drying or roasting, and the decline of the flavonols and 438 
flavanones aglycones found after these treatments. Moreover, blanching could have produced 439 
solubilization of many phenolic compounds present in the almond skin. The influence of nut 440 
processing in the phenolic composition of the skin has also been reported for peanut [22] and 441 
hazelnut skins [25]. 442 
 443 
It is known that polyphenol bioavailability is strongly influenced by their chemical structure 444 
[26, 27]. Monomeric flavan-3-ols and dimeric procyanidins (to a lower extent), would be 445 
directly absorbed in the small intestine, where they would be first conjugated, and later in the 446 
liver into methyl, glucuronide and sulfate derivatives by phase II enzymes. However, 447 
oligomers presenting a mean degree of polymerization (mDP) 3 and polymeric flavan-3-ols 448 
(proanthocyanidins) are not absorbed and reach the colon where they are metabolized by the 449 
intestinal microbiota into hydroxyphenylvalerolactones and various phenolic acids, including 450 
phenylpropionic, phenylacetic and benzoic acid derivatives, that can be further absorbed and 451 
then conjugated in the liver [28, 29]. Conversely, glycosylated polyphenols such as flavonol 452 
glycosides must be first hydrolyzed by intestinal -glucosidases before they can be absorbed, 453 
although the type of sugar that is attached to the flavonoid limits the absorption in the small 454 
intestine [27]. Flavonols containing rhamnose, would be poorly absorbed and transferred to 455 
the large intestine where they would be degraded by the rhamnosidases of the intestinal 456 
microbiota [30]. The results obtained through the human studies reported in this paper prove 457 
that the monomeric flavan-3-ols, and flavonol and flavanone glycosides coming from the 458 
almond skin are absorbed and further conjugated, as they were detected as phase-II 459 
metabolites (glucuronide, O-methyl glucuronide, sulfate and O-methyl sulfate derivatives of 460 
(epi)catechin, as well as the glucuronide conjugates of naringenin and glucuronide, and 461 
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sulfate conjugates of isorhamnetin) in both plasma and urine. Besides, these compounds plus 462 
the olygomeric flavan-3-ols (that would be not absorbed in the small intestine) would be 463 
degraded by the intestinal microbiota and lead to hydroxyphenylvalerolactones and phenolic 464 
acids (hydroxyphenylpropionic, hydroxyphenylacetic, hydroxycinnamic, hydroxybenzoic and 465 
hydroxyhippuric acids) that in urine over a 0-24 h period time. 466 
 467 
The results of the human studies also concluded that the maximum urinary excretion of the 468 
different phenolic metabolites derived from the consumption of almond skins was attained at 469 
different time over a 24-h period after the intake. For flavonol (i.e., (epi)catechin sulfate #1) 470 
and flavanone (i.e., naringenin-O-glucuronide #1) conjugates, the maximum was achieved 471 
from 2 to 6 hours, as expected for their early intestinal absorption. These data are in 472 
agreement with previous studies that reported that the maximum urinary excretion of 473 
(epi)catechin conjugated metabolites at 0-6 h [31] and at 0-2h [32] after intake of cocoa 474 
powder either with milk or water, and at 0-5 h after the intake of green tea [33]. However, for 475 
the conjugates of hydroxyphenylvaleractones [i.e., 5-(hydroxymethoxyphenyl)--476 
valerolactone sulfate #1],  the maximum was attained latter, from 6 to 24 h, as expected for 477 
their colonic origin. The later urinary excretion of flavonol conjugates (i.e., isorhamnetin 478 
sulphate) was related to the high content of isorhamnetin-3-O-rutinoside found in the almond 479 
skin [10], which would suffer a later colonic transformation. The maximum urinary excretion 480 
for microbial-derived phenolic acids (i.e., 3,4-dihydroxyphenylpropionic acid, 4-hydroxy-3-481 
methoxy-phenylacetic acid, caffeic acid and protocatechuic acid) seemed to occur after 24 h 482 
period of urine collection used in our study. This finding agrees with the study of Rios et al. 483 
[34], who reported that maximum urinary levels of 3-hydroxyphenylpropionic, 3-484 
hydroxyphenylacetic, 3-hydroxybenzoic and ferulic acid was attained between 24 and 48 h 485 
after the intake of chocolate, although no control group was considered in this study, so 486 
changes could only be compared to baseline values.  487 
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 488 
In conclusion, almond skins have proved to contain a wide range of phenolic compounds. Of 489 
particular importance in the occurrence of A- and B-type proanthocyanidins, comprising 490 
procyanidins, propelargonidins and prodelphinidins. Among the industrial processing used to 491 
remove almond skins, roasting is the most suitable type of to obtain skin extracts with the 492 
highest phenolic content. Our studies also demonstrate that almond skin polyphenols are 493 
bioavailable in humans as they were detected as phase-II and microbial-derived metabolites in 494 
plasma and urine samples. Depending on the type of metabolite, maximum urine excretion 495 
was attained at different time in the course of the 24-h period, allowing us to establish the 496 
onset of microbial metabolism. Further investigations of the potential of these phenolic 497 
metabolites as biomarkers of almond skin consumption are currently being carried out using 498 
metabolomic approaches. 499 
 500 
ACKNOWLEDGMENTS 501 
We are thankful to La Morella Nuts (Tarragona, Spain) and Puleva Biotech, S.A (Granada, 502 
Spain) for kindly supplying of the samples. This work has received financial support from the 503 
CONSOLIDER INGENIO 2010 Programme: FUN-C-FOOD CSD2007-063 from the Spanish 504 
Ministry of Science and Innovation (MICINN). I.G. was the recipient of a fellowship from the 505 
I3P Program funding by the European Social Fund. M.U-S thanks the FPI fellowship from 506 
MICINN. M.M thanks the “Ramón y Cajal” post-doctoral program. R.LL thanks the “Fondo 507 
de Investigación Sanitaria” post-doctoral program (F.I.S. CD06/00161) from MICINN. 508 
ACCEPTED MANUSCRIPT 
 21 
LITERATURE CITED 509 
[1] C.Y. Chen, K. Lapsley, J. Blumberg, A nutrition and health perspective on almonds, J. 510 
Sci. Food Agric. 86 (2006) 2245-2250. 511 
[2] S.S.K Wijeratne, M.M. Abou-Zaid, F. Shahidi, Antioxidant polyphenols in almond and its 512 
coproducts, J. Agric. Food Chem. 54 (2006) 312-318. 513 
[3] D.J.A. Jenkins, C.W.C. Kendall, A. Marchie, Dose response of almonds on coronary heart 514 
disease risk factors: Blood lipids, oxidized low-density lipoproteins, lipoprotein(a), 515 
homocysteine, and pulmonary nitric oxide: A randomized, controlled, crossover trial, 516 
Circulation 106 (2002) 1327-1332. 517 
[4] C.Y. Chen, P.E. Milbury, K. Lapsley, J.B. Blumberg, Flavonoids from almond skins are 518 
bioavailable and act synergistically with vitamins C and E to enhance hamster and human 519 
LDL resistance to oxidation, J. Nutr. 135 (2005)1366-73. 520 
[5] C.Y. Chen, P.E. Milbury, S.K. Chung, J. Blumberg, Effect of almond skin polyphenolics 521 
and quercetin on human LDL and apolipoprotein B-100 oxidation and conformation, J. Nutr. 522 
Biochem. 18 ( 2007) 785-794. 523 
[6] C.Y.O. Chen, J.B. Blumberg, Phytochemical composition of nuts, Asia Pac. J. Clin. Nutr. 524 
17 (2008) 329-332. 525 
[7] J. Aranceta, C. Perez Rodrigo, A. Naska,V. Ruiz Vadillo, A. Trichopoulou, Nut 526 
consumption in Spain and other countries. Brit. J. Nutr. 96 (Suppl. 2) (2006) S3-S11. 527 
[8] I. Garrido, M. Monagas, C. Gómez-Cordovés, B. Bartolomé B, Polyphenols and 528 
antioxidant properties of almond skins: influence of industrial processing, J. Food. Sci. 73 529 
(2008) 106-115. 530 
[9] P.E. Milbury, C.Y. Chen, G.G. Dolnikowski, J.B. Blumberg, Determination of flavonoids 531 
and phenolics and their distribution in almonds, J. Agric. Food. Chem. 54 (2006) 5027-5033. 532 
ACCEPTED MANUSCRIPT 
 22 
[10] M. Monagas, I. Garrido, R. Lebrón-Aguilar, B. Bartolome, C. Gómez-Cordovés, Almond 533 
(Prunus dulcis (Mill.) D.A. Webb) skins as a potential source of bioactive polyphenols, J. 534 
Agric. Food Chem. 55 (2007) 8498-8507. 535 
[11] P.E.C. Milbury, C.Y. Chen, H.K. Kwak, J.B. Blumberg, Almond polyphenolics feeding 536 
alters LDL oxidizability and glutathione metabolism without altering ORACpca in older 537 
adults, Free Rad. Biol. Med. 37 (2004) S38. 538 
[12] G. Mandalari, C. Nueno-Palop, G. Bisignano, M.S.J. Wickham, A. Narbad, Potential 539 
prebiotic properties of almond (Amygdalus communis L.) seeds, Applied Environ. Microbiol. 540 
74 (2008) 4264-4270. 541 
[13] G. Mandalari, G. Rich, G. Bisignano, M. Parker, K. Waldron, M. Wickham, Almond 542 
skins digestion using an in vitro dynamic gastric model: phytochemicals release and gut 543 
health, FASEB J., 23 (2009) 563.38 544 
[14] V.L. Singleton, J.A. Rossi, Colorimetry of total phenolics with 545 
phosphomolibdicphosphotungstic acid reagent, Am. J. Enol. Vitic 16 (1965) 144-158. 546 
[15] M. Urpi-Sarda, I. Garrido, M. Monagas, C. Gómez-Cordovés, A. Medina-Remón1, C. 547 
Andres-Lacueva, B. Bartolomé, Profile of plasma and urine metabolites after the intake of 548 
almond (Prunus dulcis (Mill.) D.A. Webb) polyphenols in humans, J. Agric. Food Chem. 57 549 
(2009) 10134-10142. 550 
[16] I. Garrido, M. Urpí-Sardà, M. Monagas, C. Gómez-Cordovés, P.J. Martín-Álvarez, R. 551 
Llorach, B. Bartolomé, C. Andrés-Lacueva, Targeted analysis of conjugated and microbial-552 
derived phenolic metabolites in human urine after consumption of an almond skin phenolic 553 
extract, J. Nutr. Submitted (2010). 554 
[17] F. Saura-Calixto, J. Serrano, I. Goñi, Intake and bioaccessibility of total polyphenols in a 555 
whole diet, Food Chem. 101 (2007) 492-501. 556 
ACCEPTED MANUSCRIPT 
 23 
[18] M. Urpi-Sarda, M. Monagas, N. Khan, Epicatechin, procyanidins, and phenolic 557 
microbial metabolites after cocoa intake in humans and rats, Anal. Bioanal. Chem. 394 (2009) 558 
1545-1556. 559 
[19] X. Meng, S. Sang, N. Zhu, Identification and characterization of methylated and ring-560 
fission metabolites of tea catechins formed in humans, mice, and rats, Chem. Res. Toxicol. 15 561 
(2002) 1042-1050.  562 
[20] T. Kohri, M. Suzuki, F. Nanjo, Identification of metabolites of (-)-epicatechin gallate and 563 
their metabolic fate in the rat, J. Agric. Food Chem. 51 (2003) 5561-5566. 564 
[21] M.M. Appeldoorn, J.P Vincken, A.M. Aura, P.C.H. Hollman, H. Gruppen, Procyanidin 565 
dimers are metabolized by human microbiota with 2-(3,4-dihydroxyphenyl)acetic acid and 5-566 
(3,4-dihydroxyphenyl)-- valerolactone as the major metabolites, J. Agric. Food Chem. 57 567 
(2009) 1084-1092. 568 
[22] J. Yu, M. Ahmedna, I. Goktepe, J. Dai, Peanut skin procyanidins: composition and 569 
antioxidant activities as affected by processing, J. Food Compos. Anal. 19 (2006) 364–371. 570 
[23] S. Rohn, N. Buchner, G. Driemel, M. Rauser, L.W.  Kroh, Thermal degradation of onion 571 
quercetin glucosides under roasting conditions, J. Agric. Food. Chem. 55 (2007) 1568-1573. 572 
[24] N. Buchner, A.  Krumbein, S. Rohn, L.W. Kroh, Effect of thermal processing on the 573 
flavonols rutin and quercetin, Rapid. Commun. Mass. 20 (2006) 3229-3235. 574 
[25] M. Locatelli, F. Travaglia, J.D. Cöisson, A. Martelli, C. Stévigny, M. Arlorio, Total 575 
antioxidant activity of hazelnut skin (Nocciola Piemonte PGI): Impact of different roasting 576 
conditions, Food Chem. 119 (2010) 1647-1655. 577 
[26] A. Scalbert, G. Williamson, Dietary intake and bioavailability of polyphenols, J. Nutr. 578 
130 (SUPPL. 8) (2000) 2073S-2085S. 579 
[27] C. Manach, A. Scalbert, C. Morand, C. Rémésy, L. Jiménez, Polyphenols: Food sources 580 
and bioavailability. Am. J. Clin Nutr.79 (2004) 727-747. 581 
ACCEPTED MANUSCRIPT 
 24 
[28] M.P. Gonthier, V. Cheynier, J.L. Donovan, C. Manach, C. Morand, I. Mila, C. Lapierre, 582 
C. Rémésy, A.  Scalbert, Microbial aromatic acid metabolites formed in the gut account for a 583 
major fraction of the polyphenols excreted in urine of rats fed red wine polyphenols. J. Nutr. 584 
133 (2003) 461-467. 585 
[29] M.P. Gonthier, J.L. Donovan, O. Texier, C. Felgines, C. Remesy, A. Scalbert, 586 
Metabolism of dietary procyanidins in rats, Free Rad. Biol. Med. 35 (2003) 837-844. 587 
[30] P.C.H. Hollman, J.M.P. Van Trijp, M.J.B. Mengelers, J.H.M. De Vries, M.B. Katan, 588 
Bioavailability of the dietary antioxidant flavonol quercetin in man, Cancer Letters 114 589 
(1997) 139-140. 590 
[31] E. Roura, C. Andrés-Lacueva, R. Estruch, M.L.M. Bilbao, M. Izquierdo-Pulido, R.M. 591 
Lamuela-Raventós, The effects of milk as a food matrix for polyphenols on the excretion 592 
profile of cocoa (-)-epicatechin metabolites in healthy human subjects, Br. J. Nutr. 100 (2008) 593 
846-851. 594 
[32] W. Mullen, G. Borges, J.L. Donovan, Milk decreases urinary excretion but not plasma 595 
pharmacokinetics of cocoa flavan-3-ol metabolites in humans, Am. J. Clin. Nutr. 89 (2009) 596 
1784-1791. 597 
[33] A. Stalmach, S. Troufflard, M. Serafini, A. Crozier, Absorption, metabolism and 598 
excretion of Choladi green tea flavan-3-ols by humans, Mol. Nutr. Food Res 53 (2009) S44-599 
S53. 600 
[34] L.Y. Rios, M.P. Gonthier, C. Remesy, Chocolate intake increases urinary excretion of 601 
polyphenol-derived phenolic acids in healthy human subjects, Am. J. Clin. Nutr. 77 (2003) 602 
912-918. 603 
ACCEPTED MANUSCRIPT 
 25 
Table 1. Phenolic content of blanched almond skins.  604 
Compound Content (g/g) 
Hydroxybenzoic acids and aldehydes 30.2 - 53.9 
p-Hydroxybenzoic acid 3.08 - 7.18 
Vanillic acid 11.1 - 19.2 
Protocatechuic acid 6.69 - 17.2 
Protocatechuic aldehyde 5.45 - 13.7 
  
Hydroxycinnamic acids 1.78 - 3.77 
trans p-Coumaric acid 0 - 1.06 
3-O-Caffeoylquinic acid 1.76 - 3.77 
  
Flavan-3-ols 64.8 - 121 
(+)-Catechin 20.1 - 38.3 
(-)-Epicatechin 7.17 - 26.5 
B3+B1 13.0 - 19.6 
B2 2.34 - 9.64 
B7 3.72 - 5.57 
B5 2.29 - 5.38 
C1 3.69 - 5.96 
Unknown dimer A [(epi)catechinA(epi)catechin] 2.36 - 3.51 
Unknown dimer A [(epi)catechinA(epi)catechin]  1.16 - 4.76 
Unknown dimer A [(epi)catechinA(epi)catechin] 3,21 - 4.89 
Unknown trimer A [(epi)catechin-(epi)catechinA(epi)catechin] 2.47 - 4.93 
  
Flavonol glycosides 15.6 - 130 
Kaempferol-3-O-rutinoside 5.26 - 40.7 
Kaempferol-3-O-glucoside 0 - 14.2 
Isorhamnetin-3-O-rutinoside 5.34 - 58.0 
Isorhamnetin-3-O-glucoside 5.02 - 15.3 
Quercetin-3-O-glucoside 0 - 1.71 
  
Flavanone glycosides 4.99 - 28.5 
Naringenin-7-O-glucoside 2.34 - 25.9 
Eriodictyol-7-O-glucoside 2.5 - 2.65 
  
Flavonol aglycones 9.69 - 29.6 
Kaempferol 2.75 - 12.1 
Quercetin 1.02 - 4.89 
Isorhamnetin 5.92 - 16.0 
  
Dihydroflavonol aglycones 0 - 10.3 
Dihydroquercetin 0 - 10.3 
  
Flavanone aglycones 7.25 - 19.9 
Naringenin 3.70 - 12.1 
Eriodictyol 2.98 - 7.76 
Total 165 - 370 
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Table 2. Proanthocyanidin signals ([M+Na]+) detected by MALDI-TOF-MS in almond skins extracts. 
aDP bType  Propelargonidins  Procyanidins  Prodelphinidins 
      [M+Na]+ 
calculated 
 [M+Na]+ 
observed 
  [M+Na]+ 
calculated 
 [M+Na]+ 
observed 
  [M+Na]+ 
calculated 
 [M+Na]+ 
observed 
1   
   
313.3 313.1  
  
2 A  583.1 583.2  
     
2 B  585.1 585.2  
     
2 A  
   
599.1 599.2  
  
2 B  
   
601.1 601.2  
  
2 A  
      
615.1 615.2 
2 B  
      
617.1 617.2 
3 B  873.2 873.2  
     
3 A  
   
887.2 887.2  
  
3 B  
   
889.2 889.2  
  
3 A  
      
903.2 903.2 
3 B  
      
905.2 905.2 
4 A  1159.2 1159.3  
     
4 B  1161.3 1161.2  
     
4 A  
   
1175.2 1175.2  
  
4 B  
   
1177.3 1177.2  
  
4 A  
      
1191.2 1191.2 
4 B  
      
1193.2 1193.3 
5 B  1449.3 1449.3  
     
5 A  
   
1463.3 1463.3  
  
5 B  
   
1465.3 1465.2  
  
5 A  
      
1479.3 1479.2 
5 B  
      
1482.3 1481.2 
6 B  1737.4 1737.4  
     
6 A  
   
1751.4 1752.2  
  
6 B  
   
1753.4 1754.0  
  
6 A  
      
1767.3 1767.4 
7 A  2023.4  
     
7 B  2025.4 2024.8  
     
7 A  
   
2039.4  
  
7 B  
     
2041.4 2039.6  
    
aDP: Degree of polymerization    b A: A-type proantocyanidins containing one A-type linkage; B: B-type proanthocyanidins 
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Table 3. Phenolic metabolites identified in plasma and urine after the intake of the almond polyphenol extract in humans. 
 
Non hydrolized samples  Hydrolyzed samples 
Metabolite MRM transition 
Plasma  
(at 2.5h) 
Urine 
(0-24h)  Metabolite 
MRM 
transition 
Plasma  
(at 2.5h) 
Urine 
(0-24h) 
Flavan-3-ols     Hydroxyphenylpropionic acids    
(Epi)catechin-O-glucuronide #1 465/289  Xa  3,4-Dihydroxyphenylpropionic acid 181/137 
 +b X 
(Epi)catechin-O-glucuronide #2 465/289 X X  3-Hydroxyphenylpropionic acid 165/121 + X 
(Epi)catechin-O-glucuronide #3 465/289 X X  Hydroxyphenylacetic acids  
 
 
O-methyl (epi)catechin-O-glucuronide #1 479/303 X X  3,4-Dihydroxyphenylacetic acid 167/123 + X 
O-methyl (epi)catechin-O-glucuronide #2 479/303 X X  3-Hydroxyphenylacetic acid 151/107 + X 
(Epi)catechin sulfate #1 369/289 X X  4-Hydroxy-3-methoxy-phenylacetic acid 181/137 + X 
(Epi)catechin sulfate #2 369/289 X X  Phenylacetic acid 135/91 + X 
O-methyl (epi)catechin sulfate #1 383/303 X X  Hydroxycinnamic acids  
 
 
O-methyl (epi)catechin sulfate #2 383/303 X X  m-Coumaric acid 163/119 + X 
O-methyl (epi)catechin sulfate #3 383/303  X  p-Coumaric acid 163/119 + X 
Flavanones     Caffeic acid 179/135 + X 
Naringenin-O-glucuronide #1 447/271 X X  Ferulic acid 193/134 + X 
Naringenin-O-glucuronide #2 447/271 X X  3-Hydroxy-4-methoxy-cinnamic acid 193/134 + X 
Flavonols     Hydroxybenzoic acids  
 
 
Isorhamnetin-O-glucuronide #1 491/315  X  3-Hydroxybenzoic acid 137/93 
 
X 
Isorhamnetin-O-glucuronide #2 491/315  X  4-Hydroxybenzoic acid 137/93 + X 
Isorhamnetin sulfate 395/315  X  Protocatechuic acid 153/109 + X 
Hydroxyphenylvalerolactones     Vanillic acic 167/152 + X 
5-(Dihydroxyphenyl)--valerolactone glucuronide derivative #1 383/207  X  Hydroxyhippuric acids  
 
 
5-(Dihydroxyphenyl)--valerolactone glucuronide derivative #2 383/207  X  4-Hydroxyhippuric acid 194/100 + X 
5-(Dihydroxyphenyl)--valerolactone sulfate derivative 287/207 X X  
    
5-(Hydroxy-methoxy-phenyl)--valerolactone glucuronide derivative #1 397/221  X  
    
5-(Hydroxy-methoxy-phenyl)--valerolactone glucuronide derivative #2 397/221  X      
5-(Hydroxy-methoxy-phenyl)--valerolactone sulfate derivative #1 301/221  X      
5-(Hydroxy-methoxy-phenyl)--valerolactone sulfate derivative #2 301/221  X      
Xa The concentration of the compound increased after the intake.      
+b The compound was detected but its concentration did not increase after the intake. 
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FIGURE LEGENDS 
 
Figure 1. Influence of industrial processing (blanching [B], blanching+drying [BD] and 
roasting [R]) on the content of the different phenolic groups in almond skins. A) Σ 
Hydroxybenzoic acids and aldehydes, B) Σ Hydroxycinnamic acids, C) Σ Flavan-3-ols, D) Σ 
Flavonol glycosides, E) Σ Flavanone glycosides, F) Σ Flavonol aglycones, G) Σ 
ΣDihydroflavonol aglycones, H) Σ Flavanone aglycones, I) Σ all groups. 
 
Figure 2. Changes registered in the urinary levels of some representative phenolic 
metabolites. A) (Epi)catechin sulfate #1, B) 5-(Hydroxymethoxyphenyl)--
valerolactone sulfate #1, C) Naringenin-O-glucuronide #1, D) Isorhamnetin sulfate, E) 
3,4-Dihydroxyphenylpropionic acid, F) 4-Hydroxy-3-methoxy-phenylacetic acid, G) 
Caffeic acid, H) Protocatechuic acid. 
 
Figure 3. Representation of the plane of the first and second principal components 
resulting from the application of principal components analysis (PCA) to all targeted 
metabolites for the intake group (n =12) at all time periods. Numbers in figure indicate 
the centre of each time period (1 for (-2)-0 h; 2 for 0-2 h; 3 for 2-6 h; 4 for 6-10 h, and 5 
for 10-24 h), and arrows, changes in the plane in function of the time period. 
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Figure 1.  
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Figure 2.  
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Figure 3.  
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